Filing Flows › AIM ImmunoTech (AIM) › Q2 2026 › vs Q1 2026
AIM ImmunoTech (AIM) Q2 2026 vs Q1 2026 (quarter over quarter)
AIM ImmunoTech's revenue rose $4K (+18%) from $22K in Q1 2026 to $26K in Q2 2026.
AIM ImmunoTech, Q2 2026: revenue $26K (+4% year over year), net loss $3.8M, operating cash flow −$4.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $26K | $22K | $4K | +18% |
| Net loss | $3.8M | $3.0M | $765K | +25% |
| Costs & expenses | $3.8M | $3.0M | $769K | +25% |
| Operating costs | $3.5M | $2.2M | $1.3M | +57% |
| Interest & other, net | $275K | $797K | −$522K | -65% |
| Research & development | $589K | $482K | $107K | +22% |
| General & admin | $2.9M | $1.8M | $1.2M | +67% |
| Operating cash sources | $4.6M | $2.8M | $1.9M | +68% |
| Depreciation & amortization | $44K | $43K | $1K | +2% |
| Cash used in operations | $4.6M | $2.7M | $1.9M | +69% |
| Net loss absorbed | $3.8M | $3.0M | $765K | +25% |
| Working capital & other | $846K | −$261K | $1.1M | — |
Questions
How much did AIM ImmunoTech's revenue grow quarter over quarter in Q2 2026?
AIM ImmunoTech's revenue rose $4K (+18%) from $22K in Q1 2026 to $26K in Q2 2026.